Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af NX-5948 i kombination med andre lægemidler hos voksne med B-celle-maligniteter

13. november 2026 opdateret af: Nurix Therapeutics, Inc.

Et åbent, multicenter fase 1b/2-studie til evaluering af sikkerhed og effekt af NX-5948 i kombination med andre lægemidler hos voksne med B-celle-maligniteter

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL.

The study will look at:

  • How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments
  • The effects of bexobrutideg in the body when taken with these other treatments
  • How well bexobrutideg treats CLL or SLL when taken with these other treatments

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

150

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • California
      • Irvine, California, Forenede Stater, 92618
        • Ikke rekrutterer endnu
        • City of Hope Orange County Lennar Foundation Cancer Center
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80012
        • Rekruttering
        • Rocky Mountain Cancer Centers
    • Florida
      • Coral Gables, Florida, Forenede Stater, 33146
        • Ikke rekrutterer endnu
        • University of Miami
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • Ikke rekrutterer endnu
        • University of Kansas Cancer Center
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89169
        • Ikke rekrutterer endnu
        • Comprehensive Cancer Centers of Nevada
    • New Jersey
      • Belleville, New Jersey, Forenede Stater, 07109
        • Ikke rekrutterer endnu
        • New Jersey Cancer Care
    • Oregon
      • Eugene, Oregon, Forenede Stater, 97401
        • Rekruttering
        • Oncology Associates of Oregon
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15232
        • Rekruttering
        • UPMC Hillman Cancer Center
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • SCRI Oncology Partners
    • Texas
      • Tyler, Texas, Forenede Stater, 75702
        • Rekruttering
        • Texas Oncology - Northeast

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Adequate organ and bone marrow function
  • Measurable disease by computed tomography (CT) per iwCLL
  • For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
  • For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
  • Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate

Key Exclusion Criteria:

  • Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
  • Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
  • Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
  • Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
  • Previously treated with a BTK degrader
  • Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
  • Known central nervous system (CNS) lymphoma or leukemia
  • Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
  • Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment

Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: NX-5948 + venetoclax

Administered orally once daily as a capsule

Andre navne:
  • bexobrutideg

Administered orally once daily as a tablet per prescribing information

Eksperimentel: NX-5948 + venetoclax + rituximab

Administered orally once daily as a capsule

Andre navne:
  • bexobrutideg

Administered orally once daily as a tablet per prescribing information

Administered as an intravenous (IV) infusion per prescribing information

Eksperimentel: NX-5948 + venetoclax + obinutuzumab

Administered orally once daily as a capsule

Andre navne:
  • bexobrutideg

Administered orally once daily as a tablet per prescribing information

Administered as an IV infusion per prescribing information

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Antal deltagere med behandlingsrelaterede bivirkninger
Tidsramme: Op til cirka 7 år
Op til cirka 7 år

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective response rate as determined by investigator
Tidsramme: Up to approximately 7 years

The percentage of participants with response as determined according to 2018 iwCLL guidelines; response includes complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), PR with lymphocytosis (PR-L), and nodular PR

Up to approximately 7 years
Duration of response as determined by investigator
Tidsramme: Up to approximately 7 years

Time from the date of the first response to the date of documented progressive disease or death due to any cause, whichever is earlier

Up to approximately 7 years
Progression-free survival as determined by investigator
Tidsramme: Up to approximately 7 years

Time from the date of the first dose of study drug to the date of documented progressive disease or death due to any cause, whichever is earlier

Up to approximately 7 years
Complete response rate as determined by investigator
Tidsramme: Up to approximately 7 years

The percentage of participants with CR or CRi as determined according to 2018 iwCLL guidelines; includes CR + CRi for participants with CLL.

Up to approximately 7 years
Time to response as determined by investigator
Tidsramme: Up to approximately 7 years

Time from the start date of study treatment to the date of the first assessment of a response

Up to approximately 7 years
Overall survival
Tidsramme: Up to approximately 7 years

Time from the start date of study treatment to the date of death from any cause

Up to approximately 7 years
Pharmacokinetic profile of NX-5948
Tidsramme: Up to approximately 1 year

NX-5948 concentrations in blood samples

Up to approximately 1 year
Pharmacokinetic profile of venetoclax
Tidsramme: Up to approximately 1 year

Venetoclax concentrations in blood samples

Up to approximately 1 year
Change from baseline in Global Health Status/Quality of Life on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30)
Tidsramme: Baseline and up to approximately 27 months

Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30 questionnaire to assess the overall quality of life

Baseline and up to approximately 27 months
Change from baseline in European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)
Tidsramme: Baseline and up to approximately 27 months

Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes

Baseline and up to approximately 27 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Study Director, Nurix Therapeutics, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. september 2026

Primær færdiggørelse (Anslået)

1. maj 2033

Studieafslutning (Anslået)

1. maj 2033

Datoer for studieregistrering

Først indsendt

2. april 2026

Først indsendt, der opfyldte QC-kriterier

2. april 2026

Først opslået (Faktiske)

9. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .